GET DAILY SIGNALSDiebold Nixdorf (DBD) Delivers Q3 Beat but Lowers Full-Year Outlook, Shares Fall -12%
Key Takeaways
- Diebold Nixdorf reported third quarter 2026 GAAP revenue of $994.3 million, up roughly 5% year over year and ahead of consensus estimates near $979 million.
- Adjusted earnings per share (EPS) came in at $1.34, beating the $1.31 estimate but down 4% from $1.39 a year earlier.
- Adjusted EBITDA grew 5% to $128 million, while the adjusted EBITDA margin held flat at 12.9%.
- Management lowered full-year guidance across revenue, adjusted EBITDA, adjusted EPS, and free cash flow, citing elevated memory component costs and an unfavorable product mix.
- Shares fell about 12% in the session as investors weighed the guidance reset against better-than-expected quarterly results.
- The board authorized a new $250 million share repurchase program, its largest to date.
Earnings Context and Why It Matters
Diebold Nixdorf, a global provider of banking and retail technology such as ATMs and point-of-sale systems, came into this report after a stretch of steady top-line growth and six consecutive quarters of positive free cash flow. The third quarter offered a useful test of whether that momentum would continue in the face of rising component costs and a revenue mix tilting toward lower-margin retail hardware. For investors, the updated full-year outlook provided important signals on how fast management expects cost pressures to ease and how committed the company remains to returning capital through buybacks. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Diebold Nixdorf reported GAAP revenue of $994.3 million, up 5% year over year. Retail revenue rose 16%, while the banking segment grew more modestly. GAAP net income attributable to the company was $6.6 million, and diluted GAAP EPS was $0.19, compared with $1.11 in the prior-year period.
On an adjusted basis, EPS of $1.34 exceeded the consensus estimate of $1.31 but declined 4% from $1.39 a year ago. Adjusted EBITDA increased 5% to $128 million, though the adjusted EBITDA margin remained flat at 12.9%. Free cash flow swung to a use of cash, reflecting the timing of a VAT refund and higher working capital requirements.
The most significant news came from guidance. Management lowered its full-year 2026 revenue outlook to $3.86 billion to $3.90 billion, adjusted EBITDA to $490 million to $510 million, adjusted EPS to $4.50 to $4.85, and free cash flow to $190 million to $210 million. Executives attributed the reset to elevated memory and raw-material costs, an unfavorable product mix, and the timing of certain large banking projects.
Market Reaction and Investor Sentiment
The market responded negatively to the report despite the top- and bottom-line beats. Shares fell about 12% during the session, driven primarily by the lowered full-year guidance rather than the third-quarter results themselves. The adjusted EPS midpoint of the new outlook came in well below the prior range, and the updated revenue and adjusted EBITDA targets landed below analyst expectations. Investor sentiment appeared to shift from enthusiasm about continued revenue growth to concern over margin compression, higher memory costs, and a weaker free-cash-flow trajectory. The new $250 million share repurchase authorization signaled management’s confidence in the balance sheet, but it was not enough to offset the cautious near-term outlook.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should focus on how quickly cost pressures moderate. Management indicated that most memory-related contract resets are expected to be completed by year-end, with the bulk of the cost drag easing into early 2027. Pricing actions are already underway, which could help restore product margins over the coming quarters.
Cash flow will remain a key area to watch. The third-quarter decline raised questions about the timing and sustainability of free cash flow, and the company now expects full-year 2026 free cash flow of $190 million to $210 million. How working capital normalizes and whether the delayed VAT refund is recovered will be important signals.
Finally, the company flagged a couple of large banking and retail tenders in its fourth-quarter pipeline, along with an early-stage ATM outsourcing partnership with Euronet. These developments, combined with continued operating-expense discipline and the new buyback program, will shape the narrative into 2027. Investors should monitor margin recovery, order entry, and execution of the company’s cost-savings initiatives rather than focusing on any single quarter’s results. From what I see, the new repurchase authorization adds a layer of support worth tracking.
Using Tickeron’s AI Tools for Deeper Analysis
In my analysis of Diebold Nixdorf, I turned to Tickeron’s AI Daily Buy/Sell Signals to review recent pattern activity and compare the stock’s technical setup against peers. The tool helped highlight how the post-earnings move aligned with broader sector trends. I also used the AI Trend Prediction Engine to gauge longer-term momentum signals. These resources have become a regular part of my process when evaluating quarterly updates like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DBD's RSI Indicator descends into oversold zone
The RSI Oscillator for DBD moved into overbought territory on October 28, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for DBD crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in 174 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 44 cases where DBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 61%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DBD as a result. In 33 of 55 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
The Moving Average Convergence Divergence Histogram (MACD) for DBD turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In 20 of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
DBD moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for DBD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. DBD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.034) is normal, around the industry mean (-1.214). P/E Ratio (18.977) is within average values for comparable stocks, (15.232). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.071) among similar stocks. P/S Ratio (0.606) is also within normal values, averaging (71.128).
The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PackagedSoftware
Advertisement